证券代码：300347 证券简称：泰格医药 公告编码（2025）022 号 杭州泰格医药科技股份有限公司 关于召开 2024 年度股东会、2025 年第一次 A 股类别股东会议及 2025 年第一次 H 股类别股东会议的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 一、召开会议的基本情况 1．股东会届次：2024年度股东会、2025年第一次A股类别股东会议及2025年第一次H 股类别股东会议。 2．股东会的召集人：公司董事会。 3．会议召开的合法、合规性：经公司第五届董事会第十四次会议审议通过，决定召开 2024年度股东会、2025年第一次A股类别股东会议及2025年第一次H股类别股东会议，召集 程序符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。 4．会议召开的日期、时间： 现场会议召开日期和时间：2025 年5 月30 日（星期五）上午10:00 网络投票日期和时间： （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 5 月 30 日上午 9:15—9:25，9:30—11:30 和下午13:00-15:0 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本 公 告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 （股 份 代 號：3347） 2024年股東週年大會通告 茲通告 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）謹 定 於2025年5月30日 （星 期 五）上 午 十 時 正 假座中國杭州市濱江區聚工路19號 盛大科技園A座 1樓 會 議 室 舉 行 股 東 週 年 大 會（「股東週年大會」）或 其 任 何 續 會，藉 以 考 慮 並 酌 情 批 准 下 列 決 議 案。除 文 義 另 有 所 指 外，本 通 告 所 用 詞 彙 與 本 公 司 日期為2025年4月29日 之 通 函（「通 函」）所 界 定 者 具 相 同 涵 義。 普通決議案 – 1 – (1) 考慮及批准2024年 度 報 告。 (2) 考慮及批准2024年 度 董 事 會 工 作 報 告。 (3) 考慮及批准2024年 度 監 事 ...

此乃要件 請即處理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示，概不對因本通函全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 閣下如對本通函任何內容或應採取之行動有任何疑問，應諮詢持牌證券交易商、銀行經理、律師、專業會計師或其 他專業顧問。 閣下如已將名下之杭州泰格醫藥科技股份有限公司股份全部出售或轉讓，應立即將本通函連同代表委任表格送交買 主或承讓人，或經手買賣或轉讓之銀行、或持牌證券交易商或其他代理商，以便轉交買主或承讓人。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） (1) 2024年度報告； (2) 2024年度董事會工作報告； (3) 2024年度監事會工作報告； (4) 2024年度利潤分配方案； (5) 2024年度財務決算報告； (6) 聘請公司2025年度審計機構； (7) 建議向銀行申請綜合授信額度； (8) 建議2025年 進一步變更H股發售所得款項用途； ...

證券代碼：3347 2024 泰格醫藥 可持續發展報告 目錄 CONTENTS | 領導致辭 泰格醫藥檔案 | 01 02 | | | | | 04 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 可持續發展管理 | 06 | 02 | | | | 育才與共，和衷共濟 | 58 | 05 | | | | | 合規前進，行穩致遠 | 21 | 03 | | 人才成長與發展 員工權益與福利 | 60 69 | 生態共融，和諧共生 | 80 | | 01 | | 合規經營 商業道德 | 24 28 | | 36 | 多元、平等與包容 | 73 | 應對氣候變化 | 82 86 | | | | 信息安全保護 | 30 | 創新服務，質量為本 | | 社會貢獻 | 76 | 環境保護 | | | 規範治理，誠信透明 | 16 | 知識產權保護 | 34 | 服務質量管理 | 39 | 行業發展 | 78 | | | | 董事會治理有效性 | 18 | | | 創新驅動 | 45 | | | | | | 投資者權益保障 | 2 ...

Financial Performance - In 2024, the company achieved a revenue of RMB 6.603 billion, with clinical trial technical services contributing RMB 3.178 billion and related laboratory services generating RMB 3.425 billion[12]. - Total revenue for 2024 was RMB 6,603.1 million, a decrease of 10.6% compared to RMB 7,384.0 million in 2023[16]. - Gross profit for 2024 was RMB 2,242.0 million, down 21.3% from RMB 2,848.5 million in 2023[16]. - Net profit attributable to the company's owners for 2024 was RMB 405.1 million, representing an 80.0% decline from RMB 2,024.8 million in 2023[16]. - The company's gross margin decreased to 34.0% in 2024 from 38.6% in 2023, a drop of 4.6 percentage points[16]. - Cash and cash equivalents decreased significantly by 72.3% to RMB 2,048.5 million from RMB 7,399.9 million in 2023[16]. - The company's profit for the reporting period decreased by 79.2% to RMB 447.8 million from RMB 2,149.9 million in the same period last year[75]. - Profit attributable to the company's owners fell by 80.0% to RMB 405.1 million from RMB 2,024.8 million year-on-year[75]. - The net profit margin attributable to the company's owners, excluding non-recurring gains and losses, declined from 20.0% to 12.9%[79]. Market Position and Growth - The net new contract amount for the year reached RMB 8.423 billion, representing a year-on-year growth of 7.3%, while the total backlog of contracts stood at RMB 15.776 billion, up 12.0% year-on-year[12]. - The company maintained a 12.8% market share in China's clinical outsourcing services market, having provided services for over 60% of China's listed Class I new drugs since its establishment[11]. - The total number of clinical trials serviced in 2024 included 28 listed Class I new drugs and 6 innovative medical device projects, reflecting high client recognition of the company's comprehensive service capabilities[12]. - The number of new customers developed by the company increased by 22% year-on-year, enhancing its business cooperation with a diverse client base[25]. - The company continues to maintain a leading position in the Chinese clinical research outsourcing market despite competitive pressures[24]. Operational Developments - The North American clinical operations team expanded to over 120 personnel, covering 25 states and 65 cities, collaborating with over 700 clinical centers and 100 oncology centers[13]. - The company completed the acquisition of Medical Edge in Japan and reported strong performance in South Korea, enhancing its regional capabilities[13]. - The company established a Clinical Operations Strategy Committee to enhance clinical strategy capabilities and improve project bidding success rates[26]. - The company formed targeted business development teams in specific therapeutic areas, including Cell and Gene Therapy (CGT), Radiopharmaceuticals, Weight Loss, Ophthalmology, and Central Nervous System (CNS) diseases[26]. - The company expanded its overseas business, achieving rapid growth in new orders, revenue, and profits in its international clinical CRO business in 2024[27]. Innovation and Technology - 23% of clinical trials adopted a decentralized clinical trial (DCT) hybrid model, significantly improving participant engagement and project execution flexibility[13]. - The company launched multiple remote intelligent platforms, including the CTRM remote monitoring system and the Safety Portal for safety reporting, to enhance clinical research efficiency[13]. - The company has established a digital advancement center to drive the implementation of its digital and intelligent strategies, which is now taking shape[38]. - The AI-driven medical translation business has developed a full-chain AI translation product capability, improving efficiency and accuracy in medical document translation[39]. - The application of AI technology in clinical trials is expected to improve efficiency and reduce costs, leading to innovations in existing service models[132]. Regulatory Environment and Industry Trends - The clinical research outsourcing industry in China is expected to grow at an average annual rate of 12.6% from 2024 to 2028, reaching an estimated market size of approximately RMB 75 billion by 2028[19]. - In 2024, the National Medical Products Administration approved 48 Class I innovative drugs, an increase of 8 compared to 2023, marking a historical high[20]. - The Chinese government has introduced comprehensive support policies for innovative drug development, including a plan to complete clinical trial reviews within 30 working days[22]. - The competitive landscape in the clinical CRO industry is evolving, with smaller firms beginning to scale back, while demand for CRO services is recovering as the domestic biopharmaceutical industry stabilizes[132]. - The Chinese government is actively promoting high-quality development in the biopharmaceutical industry through various policies, including financial support and optimizing review processes for innovative drug development[134]. Financial Management and Investments - Cash used in investing activities increased by 208.9% to RMB 4,739.1 million from RMB 1,534.2 million year-on-year, primarily due to cash payments for acquisitions[83]. - The company plans to utilize funds for expanding clinical trial technology services, repaying bank loans, and general corporate purposes to enhance financial management flexibility[128]. - The company plans to continue selective acquisitions and investments for growth, but failure to identify suitable targets or successfully implement these transactions could adversely affect financial performance[148]. - The company has announced the acquisition of NAMSA's China business, expanding its team and overseas service reach[48]. Risks and Challenges - The company faces potential risks from natural disasters, pandemics, and other emergencies that could adversely affect its operations, financial condition, and performance[139]. - A decline in demand for biopharmaceutical research and development services could significantly impact the company's business, financial condition, and performance[140]. - Increased competition in the global pharmaceutical contract research market poses risks related to pricing, service quality, and client relationships, which could affect the company's revenue and profitability[142]. - The company acknowledges the risk of talent loss among directors and senior management, which could disrupt business operations and growth plans[150]. Corporate Governance and Management - The board consists of seven members, including four executive directors and three independent non-executive directors[159]. - The company is committed to maintaining high standards of corporate governance through its independent directors and various committees[168]. - The management team has a strong educational background, with degrees from prestigious institutions such as Oxford University and Zhejiang University, enhancing their strategic capabilities[164][167]. - The company has established mechanisms to ensure independent opinions and advice are available to the board[197]. - The company has complied with the corporate governance code during the reporting period[189].

Group 1 - The Hang Seng Index rose by 0.12%, gaining 26 points to close at 21,998 points, while the Hang Seng Tech Index increased by 0.81% with a trading volume of HKD 97.3 billion in the morning session [1] - Ant Group plans to invest HKD 28.14 billion to acquire a controlling stake in Yau Tat Securities, leading to a surge in Alibaba-related stocks, with Yau Tat Securities rising by 20% and Alibaba Health increasing by 6% [1] - Meituan-W saw a morning increase of 3.82%, as institutions expect the competition landscape in the food delivery industry to remain stable, suggesting long-term value release for the platform [1] - Longjiang Life Science (00775) rose over 9% after showcasing various cancer vaccine data at AACR 2025 [1] - Horizon Robotics-W (09660) also increased by over 9% following a strategic partnership with Denso, with institutions indicating a positive outlook for the industry chain [1] Group 2 - Zai Lab (09911) increased by 6.48%, driven by significant growth in social business revenue in Q1, and the company is exploring overseas acquisition opportunities [2] - Lao Pu Gold (06181) rose over 6%, as institutions noted that fixed-price gold products benefit from the rising gold prices [3] - Shangmei Co., Ltd. (02145) surged by 8%, reaching a new historical high, with institutions optimistic about the long-term growth potential of the beauty care sector [4] - Tigermed (03347) fell over 2% post-earnings, with Q1 net profit attributable to shareholders decreasing by nearly 30%, although there is still room for improvement in gross margin [4] - Qingdao Beer Co., Ltd. (00168) dropped by 3.7% post-earnings, despite a 7.08% year-on-year increase in net profit for Q1 [4] - Longyuan Power (00916) declined over 6% post-earnings, with Q1 net profit attributable to shareholders decreasing by 21.82% and wind power segment revenue down by 1.89% [4] - Rongchang Bio (09995) fell by 8.21% post-earnings, despite nearly 60% year-on-year revenue growth in Q1, with losses narrowing to CNY 254 million [4]

证券代码：300347 证券简称：泰格医药 公告编码（2025）021 号 杭州泰格医药科技股份有限公司 第五届董事会第十五次会议决议公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者重 大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）第五届董事会第十五次会议于 2025年4月28日在杭州市滨江区聚工路19号盛大科技园A座19层会议室举行，本次会议以现 场与通讯表决相结合的方式召开。会议通知已于2025年4月14日以电话、电子邮件方式向全 体董事发出。会议应到董事7人，实到董事7人，本次会议由公司董事长叶小平主持。本次 会议的召开及程序符合有关法律、法规和公司章程的要求，会议合法有效。 一、 审议并通过《关于公司2025年第一季度报告的议案》。 具体内容详见中国证监会创业板指定信息披露网站同期披露的《公司2025年第一季度 报告全文》。 表决结果：同意7票，反对0票，弃权0票。 特此公告。 杭州泰格医药科技股份有限公司董事会 二〇二五年四月二十九日 1 经与会董事审议，本次会议以投票表决的方式审议通过如下决议： ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,564,143,614.71, a decrease of 5.79% compared to CNY 1,660,204,321.44 in the same period last year[5] - Net profit attributable to shareholders was CNY 165,468,741.43, down 29.61% from CNY 235,072,002.70 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 102,328,863.87, a significant decline of 66.23% compared to CNY 303,052,196.14 in the previous year[5] - Total operating revenue for the current period was ¥1,564,143,614.71, a decrease of 5.79% from ¥1,660,204,321.44 in the previous period[22] - Net profit for the current period was ¥109,980,847.86, down 64.80% from ¥312,570,373.39 in the previous period[23] - Earnings per share decreased to ¥0.19 from ¥0.27 in the previous period[23] Cash Flow - The company reported a net cash flow from operating activities of CNY 197,934,614.18, an increase of 37.26% from CNY 144,204,460.07 in the same period last year[5] - Cash generated from operating activities increased to ¥1,630,273,549.06, compared to ¥1,476,940,313.67 in the previous period[25] - The net cash flow from operating activities was $197.93 million, an increase of 37.4% compared to $144.20 million in the previous period[26] - Total cash inflow from operating activities amounted to $1.65 billion, up from $1.55 billion year-over-year[26] - Cash outflow from investing activities resulted in a net cash flow of -$657.87 million, worsening from -$119.72 million in the previous period[26] - Cash inflow from financing activities totaled $617.96 million, compared to $447.50 million in the prior year, reflecting a 38.1% increase[26] - The net cash flow from financing activities was -$103.87 million, a decline from a positive $2.42 million in the previous period[26] - The ending cash and cash equivalents balance was $1.49 billion, down from $7.42 billion at the end of the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were CNY 28,729,592,949.22, reflecting a slight increase of 0.20% from CNY 28,671,015,787.16 at the end of the previous year[5] - The company reported a total current assets of ¥5,895,369,481.10, down from ¥6,299,685,225.86 at the beginning of the period[18] - The total amount of accounts receivable is ¥1,155,388,839.63, decreased from ¥1,359,758,181.20[18] - Total liabilities increased to ¥4,820,982,910.72 from ¥4,606,536,600.57 in the previous period[20] - The company's total equity decreased to ¥23,908,610,038.50 from ¥24,064,479,186.59 in the previous period[20] Investments and Shareholder Information - The company signed new contracts worth over CNY 2 billion in Q1 2025, representing a year-on-year growth rate of 20%[11] - The company experienced a 127.11% increase in trading financial assets, totaling CNY 170,000,000.00, primarily due to the purchase of wealth management products[8] - The company’s long-term equity investments increased to ¥3,911,115,451.09 from ¥3,424,603,314.72[18] - The largest shareholder, Ye Xiaoping, holds 20.49% of shares, totaling 177,239,541 shares[13] - Total number of common shareholders at the end of the reporting period is 53,774[13] - The total number of shares held by the top ten unrestricted shareholders is 123,118,879 shares[14] - The company has a total of 171,687,044 shares under lock-up agreements, with no shares released during the period[16] Borrowings and Financial Expenses - Long-term borrowings rose by 79.72% to CNY 581,674,789.07, attributed to new long-term loans obtained during the reporting period[8] - The company reported a significant increase in financial expenses, amounting to CNY 31,748,445.86, due to reduced foreign exchange gains and the reclassification of interest from large time deposits[9] - Long-term borrowings rose significantly to ¥581,674,789.07 from ¥323,649,635.25 in the previous period[20] Strategic Planning - The company plans to continue investing in digital and intelligent technology development as part of its strategic planning[11] Other Financial Metrics - The company reported an investment income of ¥25,309,680.34, compared to a loss of ¥3,591,151.18 in the previous period[22] - Cash inflow from investment activities was $148.93 million, a decrease from $162.65 million year-over-year[26] - Cash outflow for purchasing fixed assets and other long-term assets was $48.09 million, significantly lower than $111.54 million in the previous period[26] - The company received $62.60 million from investment, compared to $21.30 million in the prior year, indicating strong investor interest[26] - The company reported a cash inflow of $555.36 million from borrowings, an increase from $373.01 million in the previous period[26]

Financial Performance - The company's operating revenue for Q1 2025 was RMB 1,564,143,614.71, a decrease of 5.79% compared to RMB 1,660,204,321.44 in the same period last year[12]. - Net profit attributable to shareholders was RMB 165,468,741.43, down 29.61% from RMB 235,072,002.70 year-on-year[12]. - The net profit after deducting non-recurring gains and losses was RMB 102,328,863.87, a significant decline of 66.23% from RMB 303,052,196.14 in the previous year[12]. - Operating profit decreased to CNY 144,504,382.40, down 60.0% from CNY 362,196,228.41 in the previous period[43]. - Net profit for the current period is CNY 109,980,847.86, a decline of 64.8% compared to CNY 312,570,373.39 in the previous period[43]. - The company reported a total comprehensive income of CNY 115,310,625.21, down 60.3% from CNY 290,331,159.48 in the previous period[44]. Cash Flow - The net cash flow from operating activities increased by 37.26% to RMB 197,934,614.18, compared to RMB 144,204,460.07 in the same period last year[12]. - The company reported a significant increase in investment cash outflows, which rose by 449.52% to RMB -657,869,238.36, mainly due to increased investments in joint ventures[23]. - Cash inflow from sales of goods and services reached ¥1,630,273,549.06, an increase of 10.3% from ¥1,476,940,313.67[47]. - Total cash outflow from operating activities was ¥1,454,545,978.13, an increase of 3.5% compared to ¥1,405,522,357.29 in the previous period[47]. - Cash inflow from financing activities amounted to ¥617,956,000.00, up 38.1% from ¥447,503,471.27 in the last period[48]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 28,729,592,949.22, reflecting a slight increase of 0.20% from RMB 28,671,015,787.16 at the end of the previous year[14]. - Total liabilities increased to CNY 4,820,982,910.72 from CNY 4,606,536,600.57, reflecting a growth of 4.6%[42]. - Long-term borrowings rose by 79.72% to RMB 581,674,789.07, attributed to new long-term loans obtained during the reporting period[19]. - The total current assets decreased from 6,299,685,225.86 RMB to 5,895,369,481.10 RMB, reflecting a decline of about 6.4%[36]. - The total liabilities decreased from 3,661,852,465.12 RMB to 3,635,724,221.91 RMB, showing a decline of approximately 0.7%[38]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 53,774[26]. - The top shareholder, Ye Xiaoping, holds a 20.49% stake, amounting to 177,239,541 shares[27]. - The company has a total of 171,687,044.00 shares under lock-up, with a release schedule of 25% per year for executives[33]. Other Financial Metrics - The weighted average return on net assets was 0.80%, down from 1.12% in the previous year, a decrease of 0.32%[12]. - The company’s income tax expense decreased by 32.43% to RMB 33,644,494.98, primarily due to a decline in pre-tax profits[22]. - The company incurred a 679.32% increase in non-operating expenses, amounting to RMB 1,038,576.02, largely due to increased donation expenditures[22]. - Earnings per share (EPS) for the current period is CNY 0.19, down from CNY 0.27 in the previous period[44]. - Other comprehensive income after tax for the current period is CNY 5,329,777.35, compared to a loss of CNY 22,239,213.91 in the previous period[43].

Core Insights - The global and US innovative drug VC&PE financing amounts are expected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the innovative drug financing environment [1] - The demand for research and development in fields such as peptides and ADCs is strong, leading to an increase in outsourcing needs in these areas [1][2] Macro Perspective - The global innovative drug financing environment is recovering, with significant growth in the demand for innovative research in specific fields like peptides and ADCs, which is expected to enhance the CXO industry's outlook [1] - According to Crunchbase, the VC&PE financing for innovative drugs in 2024 shows positive growth, marking an improvement in the financing environment [1] Micro Perspective - CXO listed companies are seeing a recovery in new orders, with many companies like WuXi AppTec, WuXi Biologics, and others reporting a year-on-year increase of over 20% in new orders [3] - The production capacity of domestic CXO companies is mature, ensuring timely delivery of orders, which is expected to lead to double-digit revenue growth for several companies in 2025 [3] Target Companies - Recommended companies to watch include WuXi AppTec (603259.SH, 02359), WuXi Biologics (02269), WuXi AppTec (02268), Kelun Pharmaceutical (002821.SZ, 06821), and others [4]